Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Clinical · Molecular biology

Site-specific outcomes and genomics in metastatic pancreatic ductal adenocarcinoma

Summary

This retrospective cohort study of 1,095 patients with metastatic pancreatic ductal adenocarcinoma (PDAC) demonstrates that the pattern of metastatic spread is strongly linked to clinical outcome and genomic detection. Patients with lung-only metastases had a significantly prolonged median overall survival of 57.6 months compared to roughly 19.5 months in patients with liver-involved disease. Tissue genomic profiling identified lower TP53 mutation frequencies and higher GNAS mutation rates in non-liver and lung-only metastases. Crucially, liquid biopsy (n = 240) showed markedly lower detection rates for KRAS (10%) and TP53 (23%) in lung-only disease, underscoring that tissue-based sequencing must be prioritized in these patients to guide KRAS-directed therapeutic decisions.

Critical appraisal

Clinical. This retrospective cohort establishes metastatic tropism as a dominant prognostic factor in metastatic PDAC, with median overall survival reaching 57.6 months in lung-only disease versus 19.3–19.5 months in liver metastases (p < 0.0001). From a predictive and therapeutic perspective, practice implications are direct (1–3 years): the poor sensitivity of plasma cell-free DNA in lung-only metastases mandates upfront tissue NGS to prevent false-negative determinations for emergent or approved KRAS-targeted regimens.

Molecular biology. Tissue NGS delineated site-specific molecular signatures, with TP53 alterations enriched in liver-involved disease (84–85% vs 67–73%, p < 0.0001) and GNAS mutations prevailing in non-liver sites (8–10% vs 2–5%, p < 0.01), while tissue KRAS mutation frequencies were uniform. However, liquid biopsy profiling (n = 240) exposed critical analytical sensitivity limitations driven by lower circulating tumor DNA shedding from pulmonary lesions, yielding an unacceptably low KRAS detection rate of 10% (versus 52% in liver metastases, p < 0.001) and highlighting the risk of assay underperformance in this subgroup.

The summary and the appraisal were written by a language model from the title and abstract of the original article. The article was selected automatically by a model, without human review. Methodology